Status:
COMPLETED
A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
19+ years
Brief Summary
This is a prospective, observational, open-label, multi-center study, which will provide detailed information about the safety and efficacy of Twynsta tablets in Korean hypertensive patients requiring...
Detailed Description
Study Design: PMS Observational study
Eligibility Criteria
Inclusion
- Inclusion criteria:
- No specific inclusion and exclusion criteria will be provided due to the exploratory character of the study. Patients who have initiated Twynsta tablets according to the recommended and approved usage in Korea will be consecutively enrolled.
- Exclusion criteria:
- No specific inclusion and exclusion criteria will be provided due to the exploratory character of the study. Patients who have initiated Twynsta tablets according to the recommended and approved usage in Korea will be consecutively enrolled.
Exclusion
Key Trial Info
Start Date :
December 21 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 18 2016
Estimated Enrollment :
674 Patients enrolled
Trial Details
Trial ID
NCT01243268
Start Date
December 21 2010
End Date
August 18 2016
Last Update
October 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NISND Center
One Or Multiple Sites, South Korea